| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/29/2008 | WO2008061308A1 Protein tyrosine phosphatase modulators |
| 05/29/2008 | WO2008061306A1 Metal delivery agents and therapeutic uses of the same |
| 05/29/2008 | WO2008046109A3 Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer |
| 05/29/2008 | WO2008045268A3 Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 05/29/2008 | WO2008045266A3 Pyrazolopyrimidiwes as cyclin dependent kinase inhibitor |
| 05/29/2008 | WO2008043846A3 New isocarbostyril alkaloid derivatives having anti-proliferative and anti-migratory activities |
| 05/29/2008 | WO2008042928A3 Oxadiazole and thiadiazole derivatives as mitotic kinesin inhibitors and methods of use thereof |
| 05/29/2008 | WO2008041246A3 Injectable depot composition and its' process of preparation |
| 05/29/2008 | WO2008038127A3 Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use |
| 05/29/2008 | WO2008027988A3 Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation |
| 05/29/2008 | WO2008024026A3 Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer |
| 05/29/2008 | WO2008021369A3 Tricyclic compounds and its use as tyrosine kinase modulators |
| 05/29/2008 | WO2008016123A1 GSK-3β INHIBITOR |
| 05/29/2008 | WO2008012440A3 Pyridazine and pyrrole compounds, processes for obtaining them and uses |
| 05/29/2008 | WO2008002641A3 Protein phosphatase inhibitors |
| 05/29/2008 | WO2007134203A3 Anticancer treatments with a combination of docetaxel and ecteinascidin |
| 05/29/2008 | WO2007121017A3 Mutations and polymorphisms of fms-like tyrosine kinase 4 |
| 05/29/2008 | WO2007120693A3 Targeted binding agents directed to upar and uses thereof |
| 05/29/2008 | WO2007106503A3 Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors |
| 05/29/2008 | WO2007084221A3 Methods and apparatus for identifying subject matter in view data |
| 05/29/2008 | WO2007075465A8 Dimers and adducts of 6-[(substituted) phenyl] triazolopyrimidines useful as anticancer agents |
| 05/29/2008 | WO2007074456A3 Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids |
| 05/29/2008 | WO2007034210A8 Deglycosylated anti-muc-1 antibodies and uses thereof |
| 05/29/2008 | US20080125484 Synthetic Lactone Formulations and Methods of Use |
| 05/29/2008 | US20080125482 Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same |
| 05/29/2008 | US20080125481 Isoflavone metabolites |
| 05/29/2008 | US20080125479 Use in inhibiting PI-3-kinase activity in mammals; cancer; Acetic acid 4-diallylaminomethylene-6-hydroxy-1- alpha -methoxymeth-yl-10 beta ,13 beta -dimethyl-3,7,17-trioxo-1,3,4,7,10,11 beta , 12,13,14 alpha ,15,16,17-dodecahydro-2-oxa-cyclopenta[ alpha ]phenanthren-11-yl ester |
| 05/29/2008 | US20080125478 Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety |
| 05/29/2008 | US20080125470 N-(3-chloro-4-fluorophenyl)-N'-hydroxy-5-(2-(methylamino)-1,3-thiazol-4-yl)isoxazole-3-carboximidamide; cancer, viral infections, depression, a neurodegenerative disorder, trauma, age-related cataracts, organ transplant rejection, or an autoimmune disease |
| 05/29/2008 | US20080125469 Thiadiazole compounds and methods of use thereof |
| 05/29/2008 | US20080125457 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 05/29/2008 | US20080125451 Vinorelbine derivatives |
| 05/29/2008 | US20080125448 Quinazoline Based EGFR Inhibitors Containing a Zinc Binding Moiety |
| 05/29/2008 | US20080125446 For example, 6-amino-2-(chloro or fluoro)-8-(arylthio(oxo))-9H-purines; complex with Heat Shock Protein 90 (HSP 90); proliferative disorders such as breast cancer |
| 05/29/2008 | US20080125440 Tyrosine kinase inhibitors containing a zinc binding moiety |
| 05/29/2008 | US20080125435 E. g., 1-(3-chloro-phenyl)-3-[1-(7-chloro-quinolin-4-yl)-piperidin-4-yl]-thiourea; regulation of ovulation, modulation of prostaglandin E2 receptors; fertilization, nidation, decidualization (e.g. placenta formation) and menstruation; hypermenorrhea, dysmenorrhea; endometriosis; anticarcinogenic agents |
| 05/29/2008 | US20080125430 New small molecule inhibitors of mdm2 and the uses thereof |
| 05/29/2008 | US20080125428 Administering N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine ditosylate monohydrate (lapatinib) with another inhibitor of epidermal growth factor receptor tyrosine kinase and/or erbB-2 (gefitinib, erlotinib); breast cancer |
| 05/29/2008 | US20080125425 Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors |
| 05/29/2008 | US20080125424 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
| 05/29/2008 | US20080125418 Benzimidazole derivatives and their use as kdr kinase protein inhibitors |
| 05/29/2008 | US20080125417 4-Tert-Butyl-N-(2-methyl-3-{2-[4-(morpholine-4-carbonyl)-phenylamino]-pyrimidin-4-yl}-phenyl)-benzamide;enzyme inhibitors of Burton's tyrosine kinase (Btk); autoimmune diseases; antiinflammatory/-arthritic agents; X-linked agammaglobulinaemia; antiallergens; osteoporosis; determining the presence Btk |
| 05/29/2008 | US20080125416 Sigma Receptor Inhibitors |
| 05/29/2008 | US20080125397 2 (SULFONYL)ETHYL N,N,N',N' tetrakis(2 chloroethyl)phosphorodia |
| 05/29/2008 | US20080125393 Methods of selectively treating diseases with specific glycosaminoglycan polymers |
| 05/29/2008 | US20080125391 administering to a mammal harboring a tumor which expresses HALRs, a Sindbis virus vector to treat the tumor, and the vector has not been modified to target a tumor-specific cellular determinant, has a preferential affinity for HALRs, a Sindbis virus E2 HALR binding domain; ganciclovir; gene therapy |
| 05/29/2008 | US20080125380 Fatty acid-anticancer conjugates and uses thereof |
| 05/29/2008 | US20080125374 Gd3-mimetic peptides |
| 05/29/2008 | US20080125369 Soluble t cell receptors |
| 05/29/2008 | US20080125363 Nonantigenic; biochemical conjugation; polyoxyethylene glycol; anticancer agents |
| 05/29/2008 | US20080125358 Methods for Chk2 inhibitor patient selection |
| 05/29/2008 | US20080125355 Endogenous Peptide and Active Subfragments Thereof |
| 05/29/2008 | US20080124743 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (u1) |
| 05/29/2008 | US20080124403 e.g., histone deacetylase inhibitor; includes electrolyte supplementation; to prevent unwanted side effects such as cardiac side effects |
| 05/29/2008 | US20080124401 Method of treating endothelial injury |
| 05/29/2008 | US20080124395 Formulations and devices for treatment or prevention of neural ischemic damage |
| 05/29/2008 | US20080124390 Antidepressants for treating manic disorders, psychosis; comprising ethyl cellulose, talc, polyvinylpyrrolidone; time-release dosage form; once daily |
| 05/29/2008 | US20080124375 Device and Methods of Sequential, Regional Delivery of Multiple Cyctotoxic Agents and Directed Assembly of Wound Repair Tissues |
| 05/29/2008 | US20080124366 Methods and Compositions for Treating Tumors |
| 05/29/2008 | US20080124358 Chemically conjugating a peptide of interest to a heterologous peptide that has been expressed on the coat protein of a cowpea mosaic virus to generate a conjugate and administering the conjugate to a host animal to increase the level of TH1-type immune response |
| 05/29/2008 | US20080124354 Her-2 protein fragments, recombinant peptides comprising same, nucleotide molecules encoding same, recombinant vaccine vectors and immunogenic compositions comprising same, and methods for inducing immune response and treating cancer, comprising same |
| 05/29/2008 | US20080124346 Chimeric metal binding protein for use in prevention and treatment of cancer, diabetes, cardiovascular disease, obesity, metabolic disease, neurodegenerative disease, gastrointestinal disease, autoimmune disease, rheumatological disease and infectious disease. |
| 05/29/2008 | US20080124336 Molecules and Methods for Inhibiting Shedding of KIM-1 |
| 05/29/2008 | US20080124334 Isolated Nucleic Acids, Vectors and Host Cells Encoding ErbB3 Antibodies |
| 05/29/2008 | US20080124332 Compositions and methods using anti-cs1 antibodies to treat multiple myeloma |
| 05/29/2008 | US20080124329 Conditioned Cell Immunization |
| 05/29/2008 | US20080124327 Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| 05/29/2008 | US20080124322 Activation and inhibition of the immune system |
| 05/29/2008 | US20080124307 Method for promoting immunotherapy |
| 05/29/2008 | US20080124302 Modified cytokine for use in treatment and prevention of viral and cell proliferative disorders |
| 05/29/2008 | US20080124301 Oligonucleotide for use in prevention and treatment of cell proliferative and nervous system disorders; antisense agents |
| 05/29/2008 | US20080124279 pectin is crosslinked with a metal cation; drug delivery system; treating colon cancer; orally administrable |
| 05/29/2008 | US20080124278 characterized by a modification at the conserved N-linked site in the CH2 domains of the Fc portion of said antibody; useful in the treatment and prevention of diseases that involve undesirable immune responses |
| 05/29/2008 | DE102006055210A1 Diätisches Lebensmittel mit erhöhter freie Radikale bindender Wirkung Dietary foods with increased free radical binding effect |
| 05/29/2008 | DE102006054205A1 Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit Use of Cytohesin inhibitors for chemical induction of longevity |
| 05/29/2008 | CA2706070A1 Therapeutic tetrahydroisoquinoline-based compositions for cancer therapy |
| 05/29/2008 | CA2679955A1 Novel chemotherapeutic agents against inflammation and cancer |
| 05/29/2008 | CA2677335A1 Indozalyl sulphonamide derivatives useful as glucocorticoid modulators |
| 05/29/2008 | CA2671517A1 Method of radio-sensitizing tumors using a radio-sensitizing agent |
| 05/29/2008 | CA2670372A1 Depsipeptides and their therapeutic use |
| 05/29/2008 | CA2670223A1 Depsipeptides and their therapeutic use |
| 05/29/2008 | CA2670083A1 Heterobicyclic metalloprotease inhibitors |
| 05/29/2008 | CA2670044A1 Heterobicyclic matrix metalloprotease inhibitors |
| 05/29/2008 | CA2670042A1 Heterobicyclic matrix metalloprotease inhibitors |
| 05/29/2008 | CA2670039A1 Novel antiproliferation antibodies |
| 05/29/2008 | CA2669982A1 Combination therapy for proliferative disorders |
| 05/29/2008 | CA2669209A1 Use of lipid containing particles comprising quillaja saponins for the treatment of cancer |
| 05/29/2008 | CA2669199A1 Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
| 05/29/2008 | CA2669083A1 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives as antitumor agents |
| 05/29/2008 | CA2668661A1 Substituted pyrazole and triazole compounds as ksp inhibitors |
| 05/29/2008 | CA2666371A1 Use of an indazolemethoxyalkanoic acid to prepare a pharmaceutical composition |
| 05/28/2008 | EP1925941A1 Method for prediction of the efficacy of vascularization inhibitor |
| 05/28/2008 | EP1925676A1 Method for assay on the effect of vascularization inhibitor |
| 05/28/2008 | EP1925621A1 Crystalline forms of zoledronic acid |
| 05/28/2008 | EP1925317A1 Stabilised mRNA tumour vaccins |
| 05/28/2008 | EP1925309A1 Novel anticancer concomitant drug |
| 05/28/2008 | EP1924691A1 Gene silencing of protease activated receptor 1 (par1) |
| 05/28/2008 | EP1924607A1 Fas binding antibodies |
| 05/28/2008 | EP1924582A2 Amide and carbamate derivatives of alkyl substituted n-[4-(4-amino-1h-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamides and methods |
| 05/28/2008 | EP1924573A1 B-raf inhibitors |